title: Vaccine and antibody-directed T cell tumour immunotherapy.
abstract: Clearer evidence for immune surveillance in malignancy and the identification of many new tumour-associated antigens (TAAs) have driven novel vaccine and antibody-targeted responses for therapy in cancer. The exploitation of active immunisation may be particularly favourable for TAA where tolerance is incomplete but passive immunisation may offer an additional strategy where the immune repertoire is affected by either tolerance or immune suppression. This review will consider how to utilise both active and passive types of therapy delivered by T cells in the context of the failure of tumour-specific immunity by presenting cancer patients. This article will outline the progress, problems and prospects of several different vaccine and antibody-targeted approaches for immunotherapy of cancer where proof of principle pre-clinical studies have been or will soon be translated into the clinic. Two examples of vaccination-based therapies where both T cell- and antibody-mediated anti-tumour responses are likely to be relevant and two examples of oncofoetal antigen-specific antibody-directed T cell therapies are described in the following sections: (1) therapeutic vaccination against human papillomavirus (HPV) antigens in cervical neoplasia; (2) B cell lymphoma vaccines including against immunoglobulin idiotype; (3) oncofoetal antigens as tumour targets for redirecting T cells with antibody strategies.
authors.affiliation: Immunology, Cancer Research UK Groups, Paterson Institute for Cancer Research and University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK.
authors.forename: Said
authors.initials: S
authors.lastname: Dermime
authors.forename: David E
authors.initials: DE
authors.lastname: Gilham
authors.forename: David M
authors.initials: DM
authors.lastname: Shaw
authors.forename: Emma J
authors.initials: EJ
authors.lastname: Davidson
authors.forename: El-Kahina
authors.initials: el-K
authors.lastname: Meziane
authors.forename: Anne
authors.initials: A
authors.lastname: Armstrong
authors.forename: Robert E
authors.initials: RE
authors.lastname: Hawkins
authors.forename: Peter L
authors.initials: PL
authors.lastname: Stern
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic; D000951:Antigens, Neoplasm / Q000276:immunology; D000956:Antigens, Viral; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active; D016219:Immunotherapy, Adoptive; D008223:Lymphoma / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D027383:Papillomaviridae / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019139:Tumor Escape; D002583:Uterine Cervical Neoplasms / Q000628:therapy / Q000821:virology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000951:Antigens, Neoplasm; D000956:Antigens, Viral; D019496:Cancer Vaccines; C031192:oncofetal antigens